ORGANIZATION
PhRMA Japan Continues Push Against Off-Year Re-Pricing for Innovative Drugs, HTA Use in Reimbursement Decisions in 2020
Japan should limit the scope of its planned “off-year” re-pricing to off-patent drugs and not apply its healthcare technology assessment (HTA) scheme to reimbursement decisions, the Pharmaceutical Research and Manufacturers of America (PhRMA) reiterated on February 19 as it laid…
To read the full story
Related Article
- Janssen’s Chris Hourigan Succeeds Jonsson as PhRMA Japan Chair
September 26, 2019
ORGANIZATION
- Pharma Labor Group Logs Wage Hikes of around 4% at July-End
August 24, 2026
- Biotech Group Calls for Post-IPO Startups to Get AMED Support
August 19, 2026
- EFPIA Executive Hails Japan’s Honebuto as “Blueprint” for Europe
August 17, 2026
- New Chuikyo Pharmacist Rep Urges 2027 Revision to Stay within 4-Minister Deal
August 3, 2026
- Ectopic Fat Research Group Launches to Push Cross-Disciplinary Studies
July 31, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





